Survey of confidence in use of stroke and bleeding risk calculators, knowledge of anticoagulants, and comfort with prescription of anticoagulation in challenging scenarios: SUPPORT-AF II study.

Abstract:

:Half of patients with atrial fibrillation (AF) and elevated stroke risk do not receive anticoagulation (AC). Explanations for undertreatment may relate to provider lack of confidence with or knowledge of the CHA2DS2-VASc stroke calculator, unfamiliarity with direct oral anticoagulants (DOACs), or uncertainty about use of AC after bleeding events or other challenging patient scenarios. We surveyed cardiology and primary care providers (PCPs) within a large healthcare system to investigate prescriber knowledge, confidence, and comfort prescribing AC for AF in challenging scenarios. Of 112 providers invited, 70 (63%) completed our survey. Compared with non-responding providers, responding providers had fewer years in practice and more often worked in a university setting. Responding providers were moderately or very confident with use of CHA2DS2-VASc calculator (90%). Cardiology providers reported substantial knowledge about DOACs (72%) compared with PCPs (33%). Both provider groups reported reluctance prescribing AC when presented with challenging patient scenarios (% providers agreeing with AC): three falls over 6 months (36%), 2 weeks after resolved gastrointestinal bleed (21%), 4 weeks after intracranial bleeding (9%), in a patient consuming five alcoholic drinks per day (44%). All providers were moderately or very confident with using the CHA2DS2-VASc calculator, but only cardiology providers reported substantial knowledge about DOACs. Our providers were reluctant to prescribe AC after bleeding and in other common situations where use of AC may be appropriate. Education of PCPs about DOACs and development of guidelines to address challenging patient scenarios may improve AC prescription rates in patients with AF.

journal_name

J Thromb Thrombolysis

authors

Amroze A,Mazor K,Crawford S,O'Day K,McManus DD,Kapoor A

doi

10.1007/s11239-019-01950-6

subject

Has Abstract

pub_date

2019-11-01 00:00:00

pages

629-637

issue

4

eissn

0929-5305

issn

1573-742X

pii

10.1007/s11239-019-01950-6

journal_volume

48

pub_type

杂志文章
  • Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin.

    abstract::Thrombosis resolution is an important component of treatment for deep vein thrombosis (DVT) and multiple anticoagulants are now available. It is unknown whether rivaroxaban contributes to a higher degree of thrombus resolution compared to conventional anticoagulation with warfarin. Our objective was to compare thrombu...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01932-8

    authors: Houghton DE,Lekah A,Macedo TA,Hodge D,Saadiq RA,Little Y,Casanegra AI,McBane RD,Wysokinski WE

    更新日期:2020-02-01 00:00:00

  • Novel sila-amide derivatives of N-acetylcysteine protects platelets from oxidative stress-induced apoptosis.

    abstract::Oxidative stress-induced platelet apoptosis is one among the many causes for the development and progression of many disorders like cardiovascular diseases, arthritis, Alzheimer's disease and many chronic inflammatory responses. Many studies have demonstrated the less optimal effect of N-acetyl cysteine (NAC) in oxida...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1450-4

    authors: Paul M,Thushara RM,Jagadish S,Zakai UI,West R,Kemparaju K,Girish KS

    更新日期:2017-02-01 00:00:00

  • Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.

    abstract::Warfarin is the most widely prescribed oral anticoagulant, but large interindividual variations exist in the dose required to achieve comparable therapeutic effects. Several clinical and genetic variables have been identified that influence warfarin dosing. However, interactions between genotype and nutrition remain u...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-013-0978-9

    authors: Saito R,Takeda K,Yamamoto K,Nakagawa A,Aoki H,Fujibayashi K,Wakasa M,Motoyama A,Iwadare M,Ishida R,Fujioka N,Tsuchiya T,Akao H,Kawai Y,Kitayama M,Kajinami K

    更新日期:2014-07-01 00:00:00

  • Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects.

    abstract::We assessed the contribution of serum homocysteine levels, an independent risk factor for vascular disease, and of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation to the variability of carotid intimal-medial thickness (IMT) in patients with non-insulin-dependent diabetes mellitus (NIDDM). Ninety-five pa...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1008962220476

    authors: Mazza A,Motti C,Nulli A,Pastore A,Andreotti F,Ammaturo V,Bianco P,Santoro E,Federici G,Cortese C

    更新日期:1999-10-01 00:00:00

  • Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis.

    abstract::Fibrinolysis is regulated by the thrombin/thrombin-activatable fibrinolysis inhibitor (TAFI) system. Thus, anticoagulants and inhibitors of TAFI are expected to accelerate fibrinolysis. The combined effects of an anticoagulant and a TAFIa inhibitor on fibrinolysis remain unknown. The aim of this study was to evaluate ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01929-3

    authors: Morishima Y,Kamisato C,Honda Y

    更新日期:2020-01-01 00:00:00

  • Calcific embolization with infective endocarditis involving the posterior mitral leaflet in a patient with underlying hypertrophic obstructive cardiomyopathy.

    abstract::We report a case of infective endocarditis (IE) involving the posterior mitral leaflet (PML) with calcific embolization in a patient with hypertrophic obstructive cardiomyopathy (HOCM). Amongst HOCM patients with IE, the anterior mitral leaflet and basal septal myocardium are almost always involved due to the endocard...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-014-1111-4

    authors: Lather N,Niziolek K,Toth P,Harris DM

    更新日期:2015-02-01 00:00:00

  • Adverse outcomes associated with inappropriate direct oral anticoagulant starter pack prescription among patients with atrial fibrillation: a retrospective claims-based study.

    abstract::Direct oral anticoagulant (DOAC) starter packs are designed for unique treatment dosing for acute venous thromboembolism (VTE). Inappropriate use of 30-day DOAC starter packs in patients with atrial fibrillation (AF) may increase the risk for bleeding events given higher dosing in the first 1-3 weeks of treatment. A r...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02358-3

    authors: Feng Y,Pai CW,Seiler K,Barnes GD

    更新日期:2021-01-03 00:00:00

  • Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.

    abstract:AIMS:Cancer patients have an increased risk for thromboembolism (TE). Factor V 1691 G-A(Leiden) (FVL) and prothrombin (PT) G20210A mutation are common inherited risk factor for TE. The aim of the study is to evaluate the prevalence of FVL and PT G20210A polymorphism in cancer patients with and without TE as compared to...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-006-9001-z

    authors: Eroglu A,Ulu A,Cam R,Kurtman C,Akar N

    更新日期:2007-02-01 00:00:00

  • Description of anti-Xa monitoring practices during low molecular weight heparin use.

    abstract::Certain patient populations (pregnancy, cancer, renal impairment, and obesity) may be at higher risk of adverse events during low molecular weight heparin (LMWH) therapy and may benefit from anti-Xa monitoring. Yet, evidence supporting a standardized approach to anti-Xa monitoring correlated to clinical outcomes is la...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01920-y

    authors: Lin A,Vazquez SR,Jones AE,Witt DM

    更新日期:2019-11-01 00:00:00

  • A descriptive evaluation of warfarin use in patients receiving hospice or palliative care services.

    abstract:PURPOSE:To describe and compare warfarin therapy use and outcomes between warfarin-receiving patients in hospice or palliative care (HPC) and not in HPC. METHODS:This retrospective, matched analysis examined warfarin-receiving patients who did (study cohort) and did not receive (control cohort) HPC services between 20...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-008-0210-5

    authors: Hill RR,Martinez KD,Delate T,Witt DM

    更新日期:2009-04-01 00:00:00

  • What is the required reperfusion period for assessment of myocardial infarct size using triphenyltetrazolium chloride staining in the rat?

    abstract::Measurements of infarct size by use of tripenyltetrazoliumchloride (TTC) is a widely accepted method used to delineate the extent of myocardial necrosis following coronary occlusion and reperfusion in various animal experiments. There is controversy, however, regarding the optimal reperfusion time for estimating the m...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1018770711705

    authors: Schwarz ER,Somoano Y,Hale SL,Kloner RA

    更新日期:2000-10-01 00:00:00

  • The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis.

    abstract::The postthrombotic syndrome (PTS) is the most common complication of deep venous thrombosis (DVT) yet has received little attention from clinicians and researchers. Clinically, PTS is characterized by chronic pain, swelling, heaviness and other signs in the affected limb. In severe cases, venous ulcers may develop. PT...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-006-5574-9

    authors: Kahn SR

    更新日期:2006-02-01 00:00:00

  • Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction.

    abstract:BACKGROUND:Sulfonylurea compounds may impair ischemic preconditioning and endogenous fibrinolysis. Increased mortality has been reported in diabetics receiving these drugs prior to admission for acute myocardial infarction when treated by direct angioplasty. Although thrombolytics are currently employed far more freque...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1012979622945

    authors: Halkin A,Roth A,Jonas M,Behar S

    更新日期:2001-10-01 00:00:00

  • Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis?

    abstract::The US Surgical Care Improvement Project (SCIP) has approved two performance measures to improve venous thromboembolism (VTE) prevention. SCIP-VTE-2 measures the proportion of surgery patients who received appropriate VTE prophylaxis within 24 h prior to surgery to 24 h after surgery. This study assesses the current r...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-009-0393-4

    authors: Deitelzweig SB,Lin J,Hussein M,Battleman D

    更新日期:2010-07-01 00:00:00

  • Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.

    abstract:BACKGROUND:Venous thromboembolism (VTE) is a significant cause of mortality and morbidity in medical patients. Although thromboprophylaxis with enoxaparin reduces the risk of VTE in these patients, the optimal duration of therapy is not currently known. The EXCLAIM (EXtended CLinical prophylaxis in Acutely Ill Medical ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-006-7732-5

    authors: Hull RD,Schellong SM,Tapson VF,Monreal M,Samama MM,Turpie AG,Wildgoose P,Yusen RD

    更新日期:2006-08-01 00:00:00

  • Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy.

    abstract::Drug-eluting stents (DES) reduce the incidence of in-stent restenosis (ISR) after primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). Whether the use of biomarkers might be of utility to identify patients who remain at risk for DES ISR after primary PCI has never been exami...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-012-0706-x

    authors: Claessen BE,Stone GW,Mehran R,Witzenbichler B,Brodie BR,Wöhrle J,Witkowski A,Guagliumi G,Zmudka K,Henriques JP,Tijssen JG,Sanidas EA,Chantziara V,Hakim D,Leon S,Xu K,Dangas GD

    更新日期:2012-08-01 00:00:00

  • Prospective Comparison of Patient Characteristics and Outcome of Non-prior Aspirin Users versus Aspirin Users with Unstable Angina or Non-Q-Wave Myocardial Infarction Treated with Combination Antithrombotic Therapy.

    abstract::The objective of this study was to determine if aspirin users presenting with acute coronary syndromes are at higher risk for subsequent clinical events. In a trial evaluating combination antithrombotic therapy in resting angina or non-Q-wave myocardial infarction (MI), patients were prospectively dichotomized on admi...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1008855220129

    authors: Cohen M,Adams PC,McBride R,Blanke H,Fuster V V

    更新日期:1997-01-01 00:00:00

  • A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion.

    abstract:BACKGROUND:We investigated the safety and efficacy of several dosing regimens of catheter-directed staphylokinase (SY162) bolus administration for the treatment of long-term venous access catheter occlusion. METHODS:This open-label, ascending dose study enrolled 24 subjects. Three doses of SY162 were evaluated in thre...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-006-0006-4

    authors: Verhamme P,Goossens G,Maleux G,Collen D,Stas M

    更新日期:2007-08-01 00:00:00

  • Venous thromboembolism: patient awareness and education in the pre-operative assessment clinic.

    abstract::Each year venous thromboembolism (VTE) causes up to 60,000 deaths in the UK, many resulting from hospital-acquired thromboses following elective surgery. National Institute for Health and Clinical Excellence (NICE) guidelines state that all elective surgical patients should receive verbal and written information pre-o...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-015-1224-4

    authors: Haymes A

    更新日期:2016-04-01 00:00:00

  • Circulating p53 and cytochrome c levels in acute myocardial infarction patients.

    abstract:BACKGROUND:Apoptosis causes myocardiocyte loss during and after myocardial infarction. Therapeutic approaches designed to arrest apoptosis would be a significant new development in the recovery of acute myocardial infarction (AMI). In order to examine apoptotic markers in the circulation, serum levels of p53 and cytoch...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-009-0328-0

    authors: Dincer Y,Himmetoglu S,Bozcali E,Vural VA,Akcay T

    更新日期:2010-01-01 00:00:00

  • Outpatient Therapy of Deep Vein Thrombosis.

    abstract::The initial treatment of acute venous thrombosis using low-molecular-weight heparin (LMWH) in the outpatient setting has been shown to be feasible, effective, and safe for selected patients when compared with in-hospital treatment using continuous intravenous heparin. There will always be a significant population of p...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1013232803747

    authors: Pineo GF,Hull RD

    更新日期:1998-01-01 00:00:00

  • Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin at Patient's Home.

    abstract::We have applied the low molecular weight heparin dalteparin as once-daily subcutaneous injections to the treatment of deep vein thrombosis (DVT) on an outpatient basis since 1994. Until today, 377 consecutive patients with DVT below the inguinal ligament have been treated at home with dalteparin. The patients administ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/A:1008866025015

    authors: Stockelberg D,Hansson E,Jonson T

    更新日期:1998-09-01 00:00:00

  • A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.

    abstract::The objective was to compare the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ticagrelor with clopidogrel among subjects of Hispanic ethnicity, as the PD and PK effects of antiplatelet agents among Hispanics are not specifically known. This was a randomised, open-label, crossover PD/PK study of 40 Hispanic...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-014-1135-9

    authors: Price MJ,Clavijo L,Angiolillo DJ,Carlson G,Caplan R,Teng R,Maya J

    更新日期:2015-01-01 00:00:00

  • Circulating lipid levels and risk of coronary artery disease in a large group of patients undergoing coronary angiography.

    abstract::A main underlying pathology of coronary artery disease is the deposition of cholesterol in the arteries supplying blood to the heart that leads to stenosis and myocardial infarction. We tested if dyslipidemia is a risk factor for coronary artery disease in the Lebanese population, and studied the role of the total cho...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s11239-014-1069-2

    authors: Platt DE,Ghassibe-Sabbagh M,Youhanna S,Hager J,Cazier JB,Kamatani Y,Salloum AK,Haber M,Romanos J,Doueihy B,Mouzaya F,Kibbani S,Sbeite H,Deeb ME,Chammas E,El Bayeh H,Khazen G,Gauguier D,Zalloua PA,Abchee AB,FGENTCA

    更新日期:2015-01-01 00:00:00

  • High positive predictive value of PAPP-A for acute coronary syndrome diagnosis in heparin-naïve patients.

    abstract::Pregnancy-associated plasma protein-A (PAPP-A) was studied as a marker of acute coronary syndrome (ACS). It has been shown that its levels are increased by heparin administration. Therefore, the aim of our study was to ascertain the diagnostic significance of PAPP-A in heparin-naïve patients and compare it with (TnI)....

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-012-0679-9

    authors: Hájek P,Macek M Sr,Pešková M,Hladíková M,Hansvenclová E,Malý M,Veselka J,Krebsová A

    更新日期:2012-07-01 00:00:00

  • Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia.

    abstract::Making a definitive diagnosis of heparin-induced thrombocytopenia (HIT) can be problematic. A prompt platelet rise following treatment has been proposed as a "post-test" criterion for diagnosis. However, the platelet response following discontinuation of heparin and initiation of a recommended alternative anticoagulan...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s11239-018-1646-x

    authors: Pon TK,Mahajan A,Rosenberg A,Amin A,Shah D,Jenkins I,Gupta V,Hofmann H,Bejjani A,White R

    更新日期:2018-05-01 00:00:00

  • Aspirin resistance and genetic polymorphisms.

    abstract::Differences in genetic makeup or polymorphisms can affect individual drug response. Detecting genetic variation may help predict how a patient will respond to a drug and could be used as a tool to select optimal therapy, tailor dosage regimens, and improve clinical outcomes. The data are replete relative to the therap...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1023/a:1022066305399

    authors: Cambria-Kiely JA,Gandhi PJ

    更新日期:2002-08-01 00:00:00

  • Characteristics and risk factors of deep vein thrombosis in hemiplegic, healthy and bilateral limbs of hemiplegic patients: a 10-year retrospective study.

    abstract::Deep vein thrombosis (DVT) in hemiplegic patients mainly affects hemiplegic limbs, DVT can also occur only in healthy limbs, and some hemiplegic patients have DVT in both limbs. Characteristics and risk factors of DVT in hemiplegic, healthy, and bilateral limbs are unknown. To describe the proportion, risk factors, ex...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02254-w

    authors: Liang F,Chao M,Li JB,Ye XM

    更新日期:2020-08-27 00:00:00

  • Sodium-hydrogen exchange and platelet function.

    abstract::On stimulation of platelets with agonists, for example, thrombin, a rapid rise in intracellular pH is observed. This alkalinization is mediated by an increase in transport activity of the Na(+)/H(+) exchanger isoform NHE1. In addition to this Na(+)/H(+) exchange mechanism, platelets express bicarbonate/chloride exchan...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1023/a:1008986329267

    authors: Rosskopf D

    更新日期:1999-07-01 00:00:00

  • Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin.

    abstract::Unfractionated heparin (UFH) plasma protein binding and elimination might be impaired in patients with chronic kidney disease (CKD-defined as creatinine clearance <60 ml/min). It is currently unknown at which UFH bolus dose persistent prolongation of activated partial thromboplastin time (aPTT) occurs in ST-segment el...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-015-1255-x

    authors: Kikkert WJ,van Brussel PM,Damman P,Claessen BE,van Straalen JP,Vis MM,Baan J Jr,Koch KT,Peters RJ,de Winter RJ,Piek JJ,Tijssen JG,Henriques JP

    更新日期:2016-04-01 00:00:00